About Our Company
Company Name:
Geninus Inc.

CEO:
Woong Yang Park

Founded:April 20, 2018

Address:70,Jeongui-ro,Songpa-gu,Seoul,4th-5thFloor(Munjeong-dong,KDU Tower)

TEL:+82-2-6949-6570
FAX:+82-2-6949-658

"Our company is a leading genomic analysis specialist, offering single-cell analysis and cancer genome companion diagnostics services. We were listed on the KOSDAQ market in November 2021."

Affiliated Company in Japan:GxD Inc.

Analytical procedure flow

We provide clear, step-by-step genetic analysis with accurate and efficient results.

01

"Receiving"

After registration, samples will be collected according to the designated method, using easily obtainable specimens like blood or saliva.

02

"Specimen QC"

Sample QC is a crucial step in achieving successful genetic analysis and research. We adhere to rigorous QC standards to maintain the highest quality.

03

"Genomic analysis"

Our specialized team utilizes cutting-edge sequencing technology to perform genetic analysis, delivering highly accurate insights into genetic data.

04

"Reporting results"

Once the analysis is complete, we will deliver a well-organized report of the results, allowing you to review them with ease and certainty.

Timeline

GENINUS Inc., established in April 2018, is a specialized biotechnology company in genomic analysis, providing innovative solutions for precision medicine and drug development.

2013
March
Establishment of Samsung Genome Institute under Samsung Medical Center and appointment of Director Woong-Yang Park
2014
August
Launch and service initiation of CancerSCAN
2016
December
Director Woong-Yang Park of Samsung Genome Institute awarded Prime Minister's Commendation
2017
June
Approval of NGS-based gene panel testing by the Ministry of Health and Welfare (CancerSCAN v1, v2)
2018
April
Establishment of Geninus Co., Ltd. (CEO Woong-Yang Park)
2018
September
Technology transfer agreement for four patents of Samsung Medical Center
2018
October
Registration of genetic testing institution with Genetic Testing Evaluation Agency
2018
October
Certification as a venture enterprise
2019
January
Launch of HealthSCAN service
2019
January
Launch of LiquidSCAN research-use service
2019
January
Launch of LiquidSCAN research-use service
2019
January
Launch of CancerSCAN IO+ service
2019
February
Series A funding secured (8.4 billion KRW)
2019
February
Certification of corporate-affiliated research institute
2019
May
Acquisition of Advanced Technology Product Certificate
2019
May
Purchase and relocation of company headquarters
2019
May
10xGenomics Visium CSP Certification
2020
April
Launch of Celinus service
2020
April
Quality assessment certification from Genetic Testing Evaluation Agency
2020
April
Launch of HealthSCAN ophthalmology service
2020
July
Pre-IPO funding secured (15.8 billion KRW)
2020
July
Pre-IPO funding secured (15.8 billion KRW)
2020
July
Clinical GMP certification
2020
August
Launch of microbiome testing (WithMe v2)
2020
December
Certification of new technology (NET)
2020
December
Free capital increase (400%)
2021
January
Headquarters expansion (Munjeong-dong, Songpa-gu, Seoul)
2021
February
Launch of HealthSCAN v2 service
2021
June
Technical evaluation grades AA, A acquired (Korea Technology Finance Corporation, Korea Health Industry Development Institute)
2021
November
Listed on KOSDAQ market
2022
June
Acquisition of European CE certification (LiquidSCAN-Lung)
2023
July
Establishment of GxD Inc.
2024
September
Supply contract for genome analysis service GxD SCRUM-Japan MONSTAR-Screen-3